Hashtag
The Times Real Estate

NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

The specified story doesn't exist

Authors: PR Newswire

Read more https://www.prnasia.com/story/archive/4610056_AE10056_0

Health & Wellness

The Importance of Having a Defibrillator in Public Spaces

Hashtag.net.au - avatar Hashtag.net.au

Life is uncertain! It is almost impossible to be 100% sure of the future, anything can happen to anyone at any time. However, in the case of Sudden Cardiac Arrests (SCA), the presence of an Automat...

Understanding Anxiety: Different Types and Treatment Options

Hashtag.net.au - avatar Hashtag.net.au

(Source) Every person experiences anxiety in some form as they face either pre-event heart palpitations before important events or constant sleep deprivation because of ongoing concerns. People exp...

How Technology Is Improving Community Support Services?

Hashtag.net.au - avatar Hashtag.net.au

(Source) Technology is literally a part of our everyday lives. Everything we do is highly dependent on technology in this day and age. The interesting part is that not just the younger generations ...